Zelebrudomide

秋去冬来，各大制药公司的三季度财报纷纷落地。肿瘤这个市场份额最大的医药细分领域历来都是各大企业的必争之地，前有国内外各大pharma凭多款“重磅炸弹”药物奋力前奔，后有百济神州、信达生物、诺诚健华携核心产品百悦泽®、达伯舒®、宜诺凯®等紧追不舍。 作者｜自由译员Isabelle   01   百济神州 单季度营收首破10亿美元 百悦泽®狂揽18亿美元 11月12日晚间，百济神州发布第三季度财报。全球业绩强势增长，首次单季度营收突破10亿美元，连续两个季度实现非GAAP经营利润盈利，GAAP经营亏损同比收窄。百济神州是all in创新药的企业。创新药研发周期长、投入大、失败率高，多年来，百济神州的研发费用在上市医药公司中遥遥领先，且连年递增，所以尚未实现收支相抵，亏损收窄即说明未来可期。据相关预测，百济神州将在2024年四季度或2025年一季度实现盈亏平衡。 百悦泽®（泽布替尼，BRUKINSA）前三季度全球销售额达18亿美元，仅三季度就创收6.9亿美元。凭借这一明星产品，百济神州加强了在慢性淋巴细胞白血病 (CLL) 领域的特许经营领导地位，并得以迅速推进后期血液学管线的关键项目。 百悦泽®是同类最佳BTKi抑制剂，也是唯一在治疗R/R CLL的头对头试验中优于强生公司的伊布替尼的药物。  在美国，百悦泽®在所有 BTKi 类药物中适应症最为宽泛，在一线和R/R CLL以及所有其他获批的 B 细胞恶性肿瘤的新患者初始治疗中处于领先地位。2023年，全球BTKi市场规模为88亿美元，其中，CLL是最大的适应症，市场规模占比80%。百悦泽®第三季度在美国的销售额同比增87%，欧洲销售额同比增长217%。在全球70多个市场获批，已治疗超10万患者。 另一重要产品PD-1抗体百泽安®（替雷利珠单抗）的销售总额为 1.63 亿美元，同比增长 13%。百泽安®已在美国商业化上市，用于食管鳞状细胞癌 (ESCC) 二线治疗，并登陆部分欧洲国家，用于ESCC二线治疗以及NSCLC一线和二线治疗。作为晚期/转移性胃癌、胃食管交界癌和 ESCC 的一线治疗药物，百泽安®获得了欧洲药品管理局人用药品委员会 (CHMP) 的肯定性意见。在中国，百泽安®已获国家药品监督管理局批准，用于NSCLC的新辅助和辅助治疗。全球业务范围也进一步扩大，在巴西（NSCLC二线、ESCC二线）、新加坡（NSCLC一线和二线、ESCC二线）、泰国（NSCLC一线和二线、ESCC一线和二线以及胃癌一线）和以色列（ESCC二线）新获批准。 同时，百济神州持续高效推进研发管线，推动 4 个新分子实体 (NMEs) 进入临床（年内已有 8 个）。公司重申有望在年底前实现10个以上NMEs进入临床的目标。 在血液学和肿瘤领域，百济神州并未满足于百悦泽®的成功和百泽安®的成长，在研的潜在同类最佳BCL2抑制剂Sonrotoclax，以及BTK CDAC（嵌合式降解激活化合物）BGB-16673都展现出了巨大的潜力。 长期以来，BCL2赛道国内只有艾伯维的维奈克拉一枝独秀，11月16日，亚盛医药力胜克拉 (APG-2575) 上市申请获CDE受理，成为国内首个申报上市的国产BCL2抑制剂，用于治疗R/R CLL/SLL（小淋巴细胞淋巴瘤），也是国内首个提交该适应症NDA的BCL2抑制剂。 除了维奈克拉和力盛克拉以外，国内还有十多款BCL2管线进入临床阶段。Sonrotoclax已进展至III期临床，开发进度靠前，无论是作为单药还是与其他药物联合用药，都展现出非同一般的有效性和安全性。与当初开展百悦泽®对比伊布替尼的头对头研究继而一战成名一样，这一次，百济神州依然选择硬刚，sonrotoclax+百悦泽®挑战维奈克拉+奥妥珠单抗的III期试验于2023年11月11日正式启动。 目前获批的BTK药物都是小分子抑制剂，容易产生耐药性问题，所以就有必要开发BTK的蛋白质降解靶向嵌合体 (PROTACs)。 据医药魔方数据库信息，截至今年10月，全球进入临床阶段的BTK降解剂不过区区6款，其中最吸引人注意的是Nurix的NX-2127和百济神州的BGB-16673。BGB-16673目前处于II期临床阶段，百济神州预计最晚明年上半年启动III期临床试验。   02   信达生物 达伯舒®领衔增长，达伯特®获批上市 同“创新药一哥”百济神州一样，“二哥”信达生物也在“游上岸”的过程中。10月30日，信达生物公布三季度报，单季度总产品收入超过23亿元，同比增长40%。结合半年报，今年1-9月，信达生物产品总收入约为62亿元，同比增长约51%。 2022年信达生物亏损25亿元，2023年亏损10亿元，2024年1-6月亏损3.9亿元，肉眼可见，亏损也在不断收窄。或许不出两年，信达生物便可达到盈亏平衡。 与百济神州以美国为最大市场不同的是，信达生物主要立足国内市场，通过医保谈判达成快速起量。肿瘤是信达生物最重视的领域，得益于广阔的适应症与国家医保目录覆盖及准入渠道优势，PD-1产品达伯舒®（信迪利单抗注射液）及其他主要产品销售表现强劲。 本季度内，新产品贡献新的增长，信达生物商业化产品组合已扩充至11款。一款新肿瘤创新靶向药物达伯特®（弗泽雷塞片，KRASG12C抑制剂）获批上市。 在肿瘤领域，信达已有9款产品获批上市，2个产品已提交上市申请，2条管线已进入III期临床试验，8条管线进入临床研究。 9款获批上市的肿瘤产品 数据来源：信达生物官网 信达生物今年获批临床的6款1类新药均为肿瘤药，其中4款是ADC。 数据来源：信达生物官网、Insight数据库   03   诺诚健华 异军突起的黑马，宜诺凯®增长75.5% 2024年第三季度，诺诚健华度实现总营收2.78亿元，同比增长73.96%， 2024 年前三季度共实现营收6.98亿元，同比增长29.8%，净亏损为2.85亿元，同比收窄47.1%。 截至9月30日，公司账上有货币资金68亿元，现金流充足。 能够交出这么耀眼的成绩单，公司的核心产品BTK抑制剂宜诺凯®（奥布替尼）居功至伟。第三季度，宜诺凯®实现销售收入2.76亿元，为该药上市以来单季最高收入，同比增长75.5%，今年前九个月，宜诺凯®实现销售收入6.93亿元，同比增长45%。 今年的国家医保目录中，宜诺凯®三项适应症：R/R CLL/SLL、R/R MCL（成人套细胞淋巴瘤）、 R/R MZL（成人边缘区淋巴瘤）都得到了医保覆盖。前两项与百悦泽®重合，但是最后一项是宜诺凯®的亮点。宜诺凯®之所以能够起量，主要就是因为它是中国首个且唯一一个针对MZL的BTK抑制剂。近年来，国内没有治疗MZL的新药获批，宜诺凯®打破了这一窘境，填补了MZL后线治疗的空缺。 目前，在血液瘤领域，诺诚健华正加速宜诺凯®一线适应症的开发。宜诺凯®在中国有三项一线适应症临床试验正在进行中，分别是一线CLL/SLL、一线MCL、一线弥漫性大B细胞淋巴瘤（DLBCL）MCD亚型。一线CLL/SLL预计今年会递交NDA。 另外，宜诺凯®在美国正在开展R/R MCL的临床试验，预计今年会递交NDA。联合BCL2抑制剂ICP-248一线治疗CLL/SLL II期临床试验也已完成患者入组。 然而，宜诺凯®的影响力绝不仅限于恶性肿瘤，在原发进展型多发性硬化(PPMS)、继发进展型多发性硬化(SPMS)、原发免疫性血小板减少症(ITP)、系统性红斑狼疮(SLE)等自免领域亦有大显身手的潜力，本文暂且不表。 11月11日，诺诚健华发布三季度业绩报告的当日，联合创始人、董事长兼首席执行官崔霁松博士说：“未来三到五年，公司预计五到六款创新药获批上市，三到四款产品进入国际化。”   写在最后   三季度报并非终篇，甚至接下来的年报也不是。莎士比亚在1611年创作的戏剧《暴风雨》中说：“凡是过往，皆为序章。”希望这些biotech在四季度能携前三季度的风雷之势，为2024年划上完美的句号。凡是未来，皆有可期。每一刻都是新的开始，更希望这些biotech能持续向前，为人类攻克疑难杂症做出重要贡献。 参考资料： Business Wire “BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates” BGNE-Investor-Deck_Q3 2024_final Insight数据库《国产首个！亚盛医药BCL-2抑制剂申报上市》、《信达生物6款抗肿瘤1类新药首次获批临床，4款为ADC》、《信达三季报：营收超23亿元，同比大增40%》 医药魔方《百济神州2024第三季度营收达71.39亿元，泽布替尼前三季度销售额超18亿美元》 诺诚健华医药有限公司 2024 年第三季度报告 诺诚健华官网、官微 信达生物官网、《截至2024年6月30日止年度 六个月中期业绩公告 (PDF)》 药智网《Biotech长跑，将分胜负》 共建Biomedical创新生态圈！ 如何加入BiG会员？

Advances in immunotherapy have ushered in a new era of treatment for follicular lymphoma (FL), particularly for patients who have experienced relapse after conventional chemotherapy regimens. This paradigm shift is characterized by the emergence of innovative therapies like CAR T-cell therapy and bispecific antibodies, which have demonstrated remarkable efficacy in targeting and eradicating lymphoma cells. CAR T-cell therapy represents a groundbreaking approach where a patient's own T-cells are genetically engineered to recognize and attack cancer cells. This personalized treatment has shown significant promise, especially for individuals who have undergone extensive previous therapies. One notable example is Axicabtagene ciloleucel (Yescarta), a CAR T-cell therapy approved for use in patients with relapsed or refractory follicular lymphoma. Clinical trials have highlighted its ability to induce durable remissions, with some patients experiencing long-term remission even after multiple prior therapies. LAS VEGAS, Nov. 28, 2024 /PRNewswire/ -- DelveInsight's ' Follicular Lymphoma Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline follicular lymphoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the follicular lymphoma pipeline domain. Key Takeaways from the Follicular Lymphoma Pipeline Report DelveInsight's follicular lymphoma pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for follicular lymphoma treatment. Key follicular lymphoma companies such as Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, Mabworks, Johnson & Johnson Innovative Medicine, Nektar Therapeutics, Xynomic Pharmaceuticals, Merck Sharp & Dohme, Jiangsu HengRui Medicine Co., Ltd., ADC Therapeutics, Bristol-Myers Squibb, Swedish Orphan Biovitrum, Zhejiang DTRM Biopharma, Immpact Bio, Galapagos, Immunitas Therapeutics, Enterome, CRISPR Therapeutics, CHO Pharma, Shanghai Blueray Biopharma, BeiGene, AstraZeneca, AVM Biotechnology, Mustang Bio, Merck, Pell Bio-Med Technology, Schrodinger Inc., Sana Biotechnology, Poseida Therapeutics, OncoNano Medicine, Inc., Nurix Therapeutics, Inc., NovalGen, Pfizer, Xencor, Wellington Zhaotai Therapies, MEI Pharma, Sutro Biopharma, Synthekine, Verismo Therapeutics, Vincerx Pharma, Novartis, Century Therapeutics, Newave Pharmaceuticals, Bio-Path Holdings, Affimed GmbH, Iksuda Therapeutics, Allogene Therapeutics, Adicet Bio, Carna Biosciences, Inc., BeiGene, Boryung Pharmaceutical, Accutar Biotechnology, Atara Biotherapeutics, AbbVie, InnoCare Pharma, NeoImmuneTech, and others are evaluating new follicular lymphoma drugs to improve the treatment landscape. Promising follicular lymphoma pipeline therapies such as Parsaclisib, TQ-B3525, Tafasitamab, MIL62, Ibrutinib, AZD0486, NKTR-255, Abexinostat, Acalabrutinib, Zilovertamab vedotin, SHR2554, Nivolumab, Loncastuximab tesirine, Golcadomide, Emapalumab, DTRM-555, Capivasertib, IMPT 314, GLPG5101, IMT-009, EO2463, CTX112, CHO-H01, BR1733, BGB-16673, BGB-10188, AZD5492, AVM0703, MB106, MK-1026, PL001, SGR-1505, SC291, SC262, P-CD19CD20-ALLO1, ONM 501, NX-5948, NX 2127, NVG-111, Mevrometostat, Plamotamab, WZTL-002, Voruciclib, STRO001, SYNCAR-001 + STK-009, SynKIR-310, VIP-152, VAY736, CNTY-101, LP-168, BP1002, IOA-244, IKS 03, ALLO-501, ADI-001, AS-1763, BGB-21447, BR101801, AC676, ATA3219, ABBV-319, ABBV-101, ICP-B02, ICP-B05, C-CAR039, Efineptakin Alfa, and others are under different phases of follicular lymphoma clinical trials. In August 2024, the company expects to file a supplemental Biologics License Application for tafasitamab for the treatment of patients with FL who have failed at least one prior systemic anti-CD20 immunotherapy or chemo-immunotherapy by the end of 2024 based on the positive Phase III results. In June 2024, a consortium of Eugene Private Equity and Korea Development Bank Private Equity announced that they would acquire 80% of South Korean vaccine maker Boryung Biopharma Co. for 320 billion won (USD 231 million). In February 2024, Incyte announced that it had entered into an asset purchase agreement with MorphoSys AG, which gives Incyte exclusive global rights for tafasitamab. Incyte will now recognize revenue and cost for all US commercialization and clinical development and MorphoSys will no longer be eligible to receive future milestone, profit split and royalty payments. In September 2023, OncoNano Medicine, Inc. announced a clinical trial supply agreement with Regeneron for the use of Libtayo (cemiplimab), a PD-1 inhibitor, in the combination stage of the first human trial of ONM-501, a dual-activating STING (STimulator of INterferon Genes) agonist and lead therapeutic development candidate. The ONM-501 first-in-human trial is a multicenter Phase Ia/b dose escalation and dose expansion study of intratumoral ONM-501 as monotherapy and in combination with Libtayo in patients with advanced solid tumors and lymphomas. OncoNano is the sponsor of the clinical trial, and Regeneron will supply cemiplimab. In May 2023, Janssen Pharmaceutical Companies of Johnson & Johnson announced that it had entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies. Under the terms of the agreement, CBMG will grant Janssen a worldwide license to develop and commercialize the CAR-T assets, except in Greater China. Janssen and CBMG will negotiate an option for Janssen to commercialize the products in the Chinese territory. Janssen will make an upfront payment of USD 245 million that will be accounted for in the second quarter as a research and development expense. Additional future payments will be based upon achieving certain development, regulatory, and sales milestones, as well as tiered royalty payments on worldwide net trade sales, excluding Greater China. Request a sample and discover the recent advances in follicular lymphoma treatment drugs @ Follicular Lymphoma Pipeline Report The follicular lymphoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage follicular lymphoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the follicular lymphoma clinical trial landscape. Follicular Lymphoma Overview Follicular lymphoma is a common type of non-Hodgkin lymphoma (NHL) that originates from B-cells, a kind of white blood cell responsible for producing antibodies. This cancer is characterized by the growth of abnormal lymphoid follicles, which can disrupt normal lymphatic function. While the exact causes of follicular lymphoma are not fully understood, certain factors may increase the risk, including age (most commonly affecting adults over 60), a family history of lymphoma, and potential environmental factors such as exposure to pesticides or chemicals. Symptoms of follicular lymphoma can vary widely but may include painless swelling of lymph nodes in the neck, armpit, or groin, unexplained weight loss, night sweats, fatigue, and fever. Some patients may remain asymptomatic for extended periods, as this type of lymphoma can progress slowly. Diagnosis typically involves a combination of physical examinations, blood tests, imaging studies (like CT scans), and a biopsy of affected lymph nodes. The biopsy helps determine the subtype and stage of the lymphoma, which is crucial for planning treatment. Treatment for follicular lymphoma depends on the stage of the disease and the patient's overall health. Options may include watchful waiting for asymptomatic cases, chemotherapy, immunotherapy (such as monoclonal antibodies), and targeted therapies. In some cases, stem cell transplants may be considered for patients with more aggressive forms or those who do not respond to initial treatments. Given the indolent nature of follicular lymphoma, ongoing management, and regular monitoring are vital for achieving the best possible outcomes. Find out more about follicular lymphoma treatment drugs @ Drugs for Follicular Lymphoma Treatment A snapshot of the Follicular Lymphoma Pipeline Drugs mentioned in the report: Learn more about the emerging follicular lymphoma pipeline therapies @ Follicular Lymphoma Clinical Trials Follicular Lymphoma Therapeutics Assessment The follicular lymphoma pipeline report proffers an integral view of the follicular lymphoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Follicular Lymphoma Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Oral, Parenteral, Subcutaneous, Topical, Transdermal Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule Therapeutics Assessment By Mechanism of Action: Phosphatidylinositol 3 kinase delta inhibitors, Phosphatidylinositol 3 kinase gamma inhibitors, Emt protein-tyrosine kinase inhibitors, Interleukin 15 receptor agonists, Histone deacetylase inhibitors, Rad51 recombinase inhibitors, Agammaglobulinaemia tyrosine kinase inhibitors, Apoptosis stimulants, Cell cycle inhibitors, Tubulin inhibitors, Tubulin polymerisation inhibitors, Enhancer of zeste homolog 2 protein inhibitors, Antibody-dependent cell cytotoxicity, Programmed cell death 1 receptor antagonists, T lymphocyte stimulants, Alkylating agents, DNA cross-linking agents Key Follicular Lymphoma Companies: Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, Mabworks, Johnson & Johnson Innovative Medicine, Nektar Therapeutics, Xynomic Pharmaceuticals, Merck Sharp & Dohme, Jiangsu HengRui Medicine Co., Ltd., ADC Therapeutics, Bristol-Myers Squibb, Swedish Orphan Biovitrum, Zhejiang DTRM Biopharma, Immpact Bio, Galapagos, Immunitas Therapeutics, Enterome, CRISPR Therapeutics, CHO Pharma, Shanghai Blueray Biopharma, BeiGene, AstraZeneca, AVM Biotechnology, Mustang Bio, Merck, Pell Bio-Med Technology, Schrodinger Inc., Sana Biotechnology, Poseida Therapeutics, OncoNano Medicine, Inc., Nurix Therapeutics, Inc., NovalGen, Pfizer, Xencor, Wellington Zhaotai Therapies, MEI Pharma, Sutro Biopharma, Synthekine, Verismo Therapeutics, Vincerx Pharma, Novartis, Century Therapeutics, Newave Pharmaceuticals, Bio-Path Holdings, Affimed GmbH, Iksuda Therapeutics, Allogene Therapeutics, Adicet Bio, Carna Biosciences, Inc., BeiGene, Boryung Pharmaceutical, Accutar Biotechnology, Atara Biotherapeutics, AbbVie, InnoCare Pharma, NeoImmuneTech, and others. Key Follicular Lymphoma Pipeline Therapies: Parsaclisib, TQ-B3525, Tafasitamab, MIL62, Ibrutinib, AZD0486, NKTR-255, Abexinostat, Acalabrutinib, Zilovertamab vedotin, SHR2554, Nivolumab, Loncastuximab tesirine, Golcadomide, Emapalumab, DTRM-555, Capivasertib, IMPT 314, GLPG5101, IMT-009, EO2463, CTX112, CHO-H01, BR1733, BGB-16673, BGB-10188, AZD5492, AVM0703, MB106, MK-1026, PL001, SGR-1505, SC291, SC262, P-CD19CD20-ALLO1, ONM 501, NX-5948, NX 2127, NVG-111, Mevrometostat, Plamotamab, WZTL-002, Voruciclib, STRO001, SYNCAR-001 + STK-009, SynKIR-310, VIP-152, VAY736, CNTY-101, LP-168, BP1002, IOA-244, IKS 03, ALLO-501, ADI-001, AS-1763, BGB-21447, BR101801, AC676, ATA3219, ABBV-319, ABBV-101, ICP-B02, ICP-B05, C-CAR039, Efineptakin Alfa, and others. Dive deep into rich insights for new drugs for follicular lymphoma treatment, visit @ Follicular Lymphoma Drugs Table of Contents For further information on the follicular lymphoma pipeline therapeutics, reach out @ Follicular Lymphoma Treatment Drugs Related Reports Follicular Lymphoma Market Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key follicular lymphoma companies including Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, and BeiGene, among others. Non-Hodgkin Lymphoma Market Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Non-Hodgkin lymphoma companies, including Roche, Pfizer, Amgen, Novartis, Teva Pharmaceuticals, Genentech, ACD Therapeutics, among others. Non-Hodgkin Lymphoma Pipeline Non-Hodgkin Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Non-Hodgkin lymphoma companies, including Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc, among others. Diffuse Large B-cell Lymphoma Market Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key DLBCL companies, including AbbVie, Genmab, Merck, Roche, Xencor, Janssen, Denovo Biopharma, Calithera Biosciences IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, Debiopharm, Seagen, Takeda, AstraZeneca, Gilead Sciences, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED